Cosmo Pharmaceuticals N.V.

SWX:COPN Stock Report

Market Cap: CHF1.2b

Cosmo Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 5/6

Cosmo Pharmaceuticals has a total shareholder equity of €433.6M and total debt of €559.0K, which brings its debt-to-equity ratio to 0.1%. Its total assets and total liabilities are €554.0M and €120.3M respectively. Cosmo Pharmaceuticals's EBIT is €12.2M making its interest coverage ratio 2.7. It has cash and short-term investments of €50.3M.

Key information

0.1%

Debt to equity ratio

€559.00k

Debt

Interest coverage ratio2.7x
Cash€50.28m
Equity€433.63m
Total liabilities€120.35m
Total assets€553.98m

Recent financial health updates

Recent updates

Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture

Mar 28
Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture

Broker Revenue Forecasts For Cosmo Pharmaceuticals N.V. (VTX:COPN) Are Surging Higher

Mar 26
Broker Revenue Forecasts For Cosmo Pharmaceuticals N.V. (VTX:COPN) Are Surging Higher

Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Popularity With Investors Is Clear

Dec 01
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Popularity With Investors Is Clear

Earnings Beat: Cosmo Pharmaceuticals N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 29
Earnings Beat: Cosmo Pharmaceuticals N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt

Nov 24
We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt

Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals

Mar 31
Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals

These 4 Measures Indicate That Cosmo Pharmaceuticals (VTX:COPN) Is Using Debt Reasonably Well

Aug 02
These 4 Measures Indicate That Cosmo Pharmaceuticals (VTX:COPN) Is Using Debt Reasonably Well

Increases to CEO Compensation Might Be Put On Hold For Now at Cosmo Pharmaceuticals N.V. (VTX:COPN)

May 20
Increases to CEO Compensation Might Be Put On Hold For Now at Cosmo Pharmaceuticals N.V. (VTX:COPN)

Cosmo Pharmaceuticals (VTX:COPN) Seems To Use Debt Quite Sensibly

Apr 03
Cosmo Pharmaceuticals (VTX:COPN) Seems To Use Debt Quite Sensibly

When Can We Expect A Profit From Cosmo Pharmaceuticals N.V. (VTX:COPN)?

Mar 07
When Can We Expect A Profit From Cosmo Pharmaceuticals N.V. (VTX:COPN)?

What Kind Of Investors Own Most Of Cosmo Pharmaceuticals N.V. (VTX:COPN)?

Feb 01
What Kind Of Investors Own Most Of Cosmo Pharmaceuticals N.V. (VTX:COPN)?

Cosmo Pharmaceuticals'(VTX:COPN) Share Price Is Down 47% Over The Past Five Years.

Dec 27
Cosmo Pharmaceuticals'(VTX:COPN) Share Price Is Down 47% Over The Past Five Years.

Financial Position Analysis

Short Term Liabilities: COPN's short term assets (€102.2M) exceed its short term liabilities (€23.2M).

Long Term Liabilities: COPN's short term assets (€102.2M) exceed its long term liabilities (€97.2M).


Debt to Equity History and Analysis

Debt Level: COPN has more cash than its total debt.

Reducing Debt: COPN's debt to equity ratio has reduced from 35% to 0.1% over the past 5 years.

Debt Coverage: COPN's debt is well covered by operating cash flow (6014.8%).

Interest Coverage: COPN's interest payments on its debt are not well covered by EBIT (2.7x coverage).


Balance Sheet


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.